Literature DB >> 35135124

Dramatic Response of a PD-L1-Positive Advanced Angiosarcoma of the Scalp to Pembrolizumab.

Rainer Hamacher1, Dietrich Kämpfe1, Kirsten Reuter-Jessen1, Christoph Pöttgen1, Lars E Podleska1, Farhad Farzaliyev1, Hans-Ulrich Steinau1, Martin Schuler1, Hans-Ulrich Schildhaus1, Sebastian Bauer1.   

Abstract

Entities:  

Year:  2018        PMID： 35135124     DOI： 10.1200/PO.17.00107

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN： 2473-4284


× No keyword cloud information.
  3 in total

1.  Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center.

Authors:  Evan Rosenbaum; Cristina R Antonescu; Shaleigh Smith; Martina Bradic; Daniel Kashani; Allison L Richards; Mark Donoghue; Ciara M Kelly; Benjamin Nacev; Jason E Chan; Ping Chi; Mark A Dickson; Mary L Keohan; Mrinal M Gounder; Sujana Movva; Viswatej Avutu; Katherine Thornton; Ahmet Zehir; Anita S Bowman; Samuel Singer; William Tap; Sandra D'Angelo
Journal:  J Immunother Cancer       Date:  2022-04       Impact factor: 12.469

2.  [Cutaneous angiosarcoma clinically presenting as Quincke's edema].

Authors:  M Albrecht; E Hadaschik; L Zimmer; E Livingstone; R Hamacher; S Bauer; D Schadendorf; S Ugurel
Journal:  Hautarzt       Date:  2021-01-13       Impact factor: 0.751

3.  Analysis of PD-1, PD-L1, and T-cell infiltration in angiosarcoma pathogenetic subgroups.

Authors:  T Tomassen; M E Weidema; M H S Hillebrandt-Roeffen; C van der Horst; I M E Desar; U E Flucke; Yvonne M H Versleijen-Jonkers
Journal:  Immunol Res       Date:  2022-01-19       Impact factor: 2.829
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.